Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Clinical Genitourinary Cancer
- Management of metastatic urothelial cancer: the role of surgery as an adjunct to chemotherapy.Can Urol Assoc J. 2009; 3: S228-S231
- Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder?.J Urol. 2003; 169: 2113-2117
- Pattern of failure and survival of patients with metastatic urothelial tumors relapsing after cis-platinum-based chemotherapy.J Urol. 1994; 151 (discussion: 600-1): 598-600
- Impact of multimodal treatment on survival in patients with metastatic urothelial cancer.Eur Urol. 2007; 52: 1106-1113
- Impact of surgical resection of bladder cancer metastases refractory to systemic therapy on performance score: a phase II trial.Urology. 2001; 57: 55-59
- Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma.J Clin Oncol. 1999; 17: 2546-2552
- Is there a role for surgery in the management of metastatic urothelial cancer? The M.D. Anderson experience.J Urol. 2004; 171: 145-148
- Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05).Eur Urol. 2009; 55: 1293-1299
- Risk factors for patients with pelvic lymph node metastases following radical cystectomy with en bloc pelvic lymphadenectomy: concept of lymph node density.J Urol. 2003; 170: 35-41
- Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients.J Clin Oncol. 2001; 19: 666
- The rationale for en bloc pelvic lymph node dissection for bladder cancer patients with nodal metastases: long-term results.J Urol. 1993; 149: 753
- Lymph node-positive bladder cancer treated with radical cystectomy and lymphadenectomy: effect of the level of node positivity.Eur Urol. 2012; 61: 1025-1030
- Patterns of local recurrence after radical cystectomy in a contemporary series of patients with muscle-invasive bladder cancer.World J Urol. 2012; 30: 821-826
- Late oncological occurences following radical cystectomy in patients with bladder cancer.Eur Urol. 2003; 43: 489-494
- Local recurrence after radical cystectomy for invasive bladder cancer: an analysis of predictive factors.Urology. 2004; 64: 744-748
- Radical cystectomy and extended pelvic lymphadenectomy: survival of patients with lymph node metastasis above the bifurcation of the common iliac vessels treated with surgery only.J Urol. 2007; 178 (discussion: 1223-4): 1218-1223
- Super extended versus extended pelvic lymph node dissection in patients undergoing radical cystectomy for bladder cancer: a comparative study.J Urol. 2011; 186: 1261-1268
- Integrating metastasectomy in the management of advanced urological malignancies—where are we in 2005?.J Urol. 2006; 176: 1921-1926
- Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study.J Clin Oncol. 1993; 11: 2150-2157
- Radiotherapy with or without chemotherapy in muscle invasive bladder cancer.N Engl J Med. 2012; 366: 1477-1488
- Words of wisdom. Re: Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer.Eur Urol. 2013; 63: 181-182
- The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response.Oncologist. 2000; 5: 471-476
- Phase I-II RTOG study (99–06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy.Urology. 2009; 73: 833-837
- Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial.Lancet Oncol. 2013; 14: 863-872
- Receipt of aggressive therapies for muscle-invasive bladder cancer: results from the national cancer data base.J Clin Oncol. 2012; 30 (abstract 272)
- Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer.Urology. 2002; 60: 62
- Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results.J Clin Oncol. 2002; 20: 3061
- Concurrent ipilimumab and radiotherapy in patients with metastatic melanoma: a retrospective analysis.J Clin Oncol. 2015; 33 ([Abstract]) (abstract e20048): 5s
- Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired.Blood. 2009; 114: 1537-1544
- Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.Immunol Rev. 2008; 224: 166-182
- Molecular pathways: next-generation immunotherapy–inhibiting programmed death-ligand 1 and programmed death-1.Clin Cancer Res. 2012; 18: 6580-6587
Kear S. FDA grants breakthrough therapy designation to MPDL3280A for bladder cancer. TargetedOnc website. Available at: http://www.targetedonc.com/conference/immunotherapy-news-asco-2014/fda-grants-breakthrough-therapydesignation-to-mpdl3280a-for-bladder-cancer/1#sthash. Published June 1, 2014. Accessed November 19, 2014.
- Inhibition of PDL1 by MPDL3280A leads to clinical activity in pts with metastatic urothelial bladder cancer (UBC).Ann Oncol. 2014; 25 (Abstract 8080): iv280-iv304
- Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.Immunity. 2007; 27: 111-122
A study of MPDL3280A in patients with locally advanced or metastatic urothelial bladder cancer. ClinicalTrials.gov website. Available at: http://clinicaltrials.gov/ct2/show/NCT02108652?term=NCT02108652&rank=1. Accessed November 19, 2014.
- A phase 1b study of pembrolizumab (Pembro; MK-3475) in patients (pts) with advanced urothelial tract cancer.Ann Oncol. 2014; 25 (abstract LBA23): 1-41
Study of pembrolizumab (MK-3475) in participants with advanced solid tumors (MK-3475-012/KEYNOTE-012). ClinicalTrials.gov website. Available at: http://clinicaltrials.gov/show/NCT01848834. Accessed November 19, 2014.
Verbal communication with PI of concurrent RT with anti PDL-1 inhibitor followed by anti-PDL-1 inhibitor- Dr. M. Joshi) (unpublished data).